|Advancing clinical trial design in pulmonary hypertension. (Volume 3) - Grieve, Andy P.|
This article is from Pulmonary Circulation, volume 3.AbstractIn pulmonary hypertension, as in many other diseases, there is a need for a smarter approach to evaluating new treatments. The traditional randomized controlled trial has served medical science well, but constrains the development of treatments for rare diseases. A workshop was established to consider alternative clinical trial designs in pulmonary hypertension and here discusses their merits, limitations and challenges to implementati...
|Mémoires sur Socrate (entretiens mémorables) [microform] - Xenophon|
|The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension. (Volume 2) - Zeng, Wei-Jie|
This article is from Pulmonary Circulation, volume 2.AbstractThe survival rates of Chinese patients with idiopathic pulmonary arterial hypertension (IPAH) and familial pulmonary arterial hypertension (PAH) on conventional therapy at 1 and 3 years were 68.0% and 38.9%, respectively. Our aim was to update recent knowledge on the demographics, clinical course, hemodynamic features, disease management, and survival of adult patients with IPAH...